The first ASHP-accredited PGY1 Community-Based Pharmacy Residency Program in a compounding pharmacy in the U.S.
ATLANTA, Nov. 13, 2025 /PRNewswire/ — Revelation Pharma, a leading national network of 503A and 503B compounding pharmacies, today announced that its Postgraduate Year One (PGY1) Community-Based Pharmacy Residency Program has been granted accreditation for the maximum 8-year term by the American Society of Health-System Pharmacists (ASHP) in partnership with the American Pharmacists Association.
This distinction makes Revelation Pharma – Innovation Compounding the first ASHP-accredited PGY1 Community-Based Pharmacy Residency Program in a compounding pharmacy in the country to achieve the maximum accreditation duration, underscoring the company’s ongoing commitment to advancing excellence, education, and innovation within the field of pharmacy compounding.
“Our residency program was designed to bridge clinical pharmacy with advanced compounding practice, offering residents an experience unlike any other in the country,” said Shawn Hodges, PharmD, CEO of Revelation Pharma. “This recognition affirms the value of specialized training in compounding and the importance of preparing the next generation of pharmacists for evolving patient needs.”
Revelation Pharma’s PGY1 program provides residents with hands-on experience across both sterile and non-sterile compounding, quality assurance, regulatory compliance, business management, and personalized medication management. Residents gain diverse patient care experiences, including ambulatory care, dermatology, hormone therapy, pain management, and nutritional wellness, through the company’s expansive national network of pharmacies and patient care partners.
“We are grateful to ASHP’s Commission on Credentialing for granting us the privilege of pursuing accreditation in such a novel practice setting,” said Brandon Sucher, PharmD, Residency Program Director. “The guidance from ASHP’s survey team and residency program workshops helped us develop a roadmap for excellence. This 8-year accreditation is a testament to the strength and sustainability of our program, and reflects the relentless dedication of our preceptors, leadership, and residents to upholding the highest standards in patient care and compounding education.”
Revelation Pharma continues to set the standard for excellence in compounding by combining innovation, education, and collaboration to advance the profession of pharmacy and improve patient outcomes nationwide.
For more information on Revelation Pharma’s PGY1 Residency Program, visit: https://revelationpharma.com/revelation-group-pgy1
About Revelation Pharma
Revelation Pharma is a leading national network of 503A and 503B compounding pharmacies serving patients, prescribers, hospitals, and healthcare organizations across the United States. With expertise across a wide range of therapeutic areas—including women’s health, men’s health, dermatology, cosmeceuticals, IV/IM nutrition, pain management, and more—Revelation Pharma is dedicated to advancing personalized medicine through quality, innovation, and patient-first care. To learn more, visit our website, and follow us on Facebook, YouTube, LinkedIn and Instagram.
Media Contact:
Chelsea Kershaw
909-573-7237
SOURCE Revelation Pharma